Mural Oncology plc (MURA) Research

Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.

Market snapshot

Symbol
MURA
Price
$2.04
Day change
0.00%
Market cap
$35.4M
P/E ratio
-0.30x
52-week range
0.95-4.74
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Alterity Therapeutics Limited (ATHE)
  • BioAtla, Inc. (BCAB)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Evaxion Biotech A/S (EVAX)
  • Generation Bio Co. (GBIO)
  • Jasper Therapeutics, Inc. (JSPR)
  • Liminatus Pharma, Inc. Class A Common Stock (LIMN)
  • SAB Biotherapeutics, Inc. (SABS)

Recent insider activity

  • Hickey Benjamin — D-Return (15021 shares) on 2025-12-05
  • Hickey Benjamin — D-Return (8637 shares) on 2025-12-05
  • Hickey Benjamin — D-Return (8462 shares) on 2025-12-05
  • Loew Caroline — D-Return (293059 shares) on 2025-12-05
  • Loew Caroline — D-Return (379690 shares) on 2025-12-05

Open Mural Oncology plc (MURA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.